<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

Statistical Models Determine Stem-Cell Transplant Effectiveness

Phase II Elotuzumab Study Demonstrates 33 Months PFS

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

Biomarker Test Outperforms PSA and Gleason Score in Study

NCI CTEP Approved Trials For the Month of July

FDA Approves Implant For Breast Reconstruction

Newcomers Undercut Price of BRCA Test; Myriad Lawsuits Claim Patent Infringement

Van Etten To Take Over As Director Of UC Irvine Chao Cancer Center

R01 and P01 Grants Will No Longer Support Phase III Clinical Trials

House Committee Seeks Review Of Indirect Costs Of NIH Grantees